ValuEngine cut shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) from a hold rating to a sell rating in a research report report published on Tuesday morning.
IRWD has been the topic of several other research reports. J P Morgan Chase & Co restated a neutral rating and issued a $19.00 target price (down previously from $20.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, July 21st. BidaskClub cut Ironwood Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a strong sell rating to a hold rating in a research note on Monday, July 17th. Cowen and Company reiterated an outperform rating and set a $20.00 price objective on shares of Ironwood Pharmaceuticals in a research note on Sunday, July 23rd. Finally, Mizuho reiterated a buy rating and set a $22.00 price objective on shares of Ironwood Pharmaceuticals in a research note on Sunday, July 23rd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $18.29.
Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $15.51 on Tuesday. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. Ironwood Pharmaceuticals has a 12 month low of $13.43 and a 12 month high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million for the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The business’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.18) EPS. analysts predict that Ironwood Pharmaceuticals will post -1.12 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) Cut to Sell at ValuEngine” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/18/ironwood-pharmaceuticals-inc-irwd-cut-to-sell-at-valuengine.html.
Several institutional investors have recently made changes to their positions in IRWD. Parametric Portfolio Associates LLC increased its holdings in shares of Ironwood Pharmaceuticals by 3.7% during the 1st quarter. Parametric Portfolio Associates LLC now owns 80,693 shares of the biotechnology company’s stock worth $1,377,000 after acquiring an additional 2,913 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 24,051 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 62 shares during the last quarter. Teachers Advisors LLC increased its holdings in shares of Ironwood Pharmaceuticals by 2.5% during the 1st quarter. Teachers Advisors LLC now owns 231,163 shares of the biotechnology company’s stock worth $3,944,000 after acquiring an additional 5,567 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 5.7% during the 1st quarter. Vanguard Group Inc. now owns 10,505,461 shares of the biotechnology company’s stock worth $179,223,000 after acquiring an additional 562,179 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $3,181,000. Institutional investors own 98.83% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.